aspirin has been researched along with Carotid Artery Diseases in 158 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Carotid Artery Diseases: Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to evaluate the effect of triflusal (2-acetyloxy-4-trifluoromethyl benzoic acid), an orally active antiplatelet agent, on arteriosclerosis progression, a pilot, parallel, double-dummy, double-blind clinical trial vs acetylsalicylic acid (ASA) was carried out in patients with subclinical atherosclerotic lesions." | 9.09 | Effects of triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound. ( Ambrosoli, L; Belcaro, G; Cesarone, MR; DeSanctis, MT; Fugazza, L; Girardello, R; Incandela, L; Laurora, G; Peracino, L; Poli, A, 1999) |
| "PubMed and MEDLINE searches (up to January 2010) were performed to identify primary literature, using search terms including aspirin, stroke prevention, acute ischemic stroke, acetylsalicylic acid, atrial fibrillation, myocardial infarction, and carotid endarterectomy." | 8.86 | Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. ( Ansara, AJ; Arif, SA; Koehler, JM; Nisly, SA; Nordmeyer, ST, 2010) |
| "End-pouch ECA aneurysms were created in adult rats and were then embedded with either platinum or HydroCoils." | 7.83 | Aspirin and Clopidogrel Inhibit Aneurysm Healing after HydroCoil Implantation in External Carotid Artery Aneurysm Model. ( Chaudhary, N; Gemmete, JJ; Li, P; Pandey, AS; Thompson, BG; Xi, G; Zhang, C, 2016) |
| "Further to characterize the processes involved in the FeCl3-induced thrombosis model, we determined the effect of aspirin, heparin, hirudin, trans-4-(aminomethyl) cyclohexane carboxylic acid (AMCHA), thrombocytopenia, and flow modifications on time to occlusion (TTO) and thrombus weight (TW) in the rat carotid artery." | 7.70 | Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. ( Kambayashi, J; Lockyer, S, 1999) |
| "Thromboxane A2 (TXA2) biosynthesis was studied in healthy subjects, patients with chronic cerebral infarction, patients under chronic aspirin treatment and patients with atrial fibrillation." | 7.68 | Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction. ( Hayashi, Y; Nakahama, H; Nakanishi, T; Shimizu, S; Sugita, M; Takiguchi, A; Uyama, O; Yamamoto, S, 1992) |
| "Methods- Carotid atherosclerosis was analyzed either as the presence of mild (ie, 20%-49%) atherosclerotic stenosis or, separately, as the presence of carotid plaque." | 6.90 | Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. ( Amarenco, P; Berkowitz, SD; Bornstein, N; Camps-Renom, P; Connolly, SJ; Cucchiara, B; Gagliardi, RJ; Hart, RG; Korompoki, E; Lang, W; Lavados, P; Makaritsis, K; Marti-Fabregas, J; Meseguer, E; Milionis, H; Mundl, H; Ntaios, G; Papavasileiou, V; Siegler, JE; Swaminathan, B; Vemmos, K, 2019) |
| "We performed an exploratory analysis of the interaction of the treatment effects of aspirin plus clopidogrel versus aspirin monotherapy, stratified by presence of ipsilateral nonstenotic carotid disease in patients with minor ischemic stroke in the POINT trial." | 5.34 | Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial. ( Brorson, JR; Bulwa, Z; Pinto, CB; Saleh Velez, FG, 2020) |
| " The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037)." | 5.27 | Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Aboyans, V; Alings, M; Anand, SS; Avezum, AA; Bangdiwala, SI; Bhatt, DL; Bosch, J; Branch, K; Chen, E; Commerford, PJ; Connolly, SJ; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Kakkar, AK; Keltai, K; Leong, DP; Lewis, BS; Lopez-Jaramillo, P; Maggioni, AP; Misselwitz, F; O'Donnell, M; Pogosova, N; Ryden, L; Störk, S; Vanassche, T; Varigos, JD; Vinereanu, D; Widimsky, P; Yusuf, S; Zhu, J, 2018) |
| "In order to evaluate the effect of triflusal (2-acetyloxy-4-trifluoromethyl benzoic acid), an orally active antiplatelet agent, on arteriosclerosis progression, a pilot, parallel, double-dummy, double-blind clinical trial vs acetylsalicylic acid (ASA) was carried out in patients with subclinical atherosclerotic lesions." | 5.09 | Effects of triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound. ( Ambrosoli, L; Belcaro, G; Cesarone, MR; DeSanctis, MT; Fugazza, L; Girardello, R; Incandela, L; Laurora, G; Peracino, L; Poli, A, 1999) |
| "We compared the outcomes of 2,500 patients who suffered from previous cerebrovascular disorders (transient ischemic attacks, reversible ischemic neurologic deficits, or completed strokes) treated with acetylsalicylic acid plus dipyridamole or matched placebo and followed for 2 years." | 5.06 | European Stroke Prevention Study. ESPS Group. ( , 1990) |
| " The 2017 European Society of Cardiology (ESC)/European Society for Vascular Surgery (ESVS) guidelines recommend for patients with asymptomatic CAAD ≥60% the use of aspirin 75 to 100 mg once daily or clopidogrel 75 mg once daily at the exception of patient at very high bleeding risk." | 5.01 | Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. ( Aboyans, V; Anand, SS; Bauersachs, R; Bosch, J; Debus, ES; Eikelboom, JW; Mazzolai, L; Nehler, M; Nikol, S; Pastori, D; Patel, MR; Ricco, JB; Tanguay, JF; Verhamme, P; Violi, F, 2019) |
| " Three preventive strategies were identified: (i) intra-operative transcranial Doppler (TCD) ultrasound and completion angioscopy which virtually abolished intra-operative stroke, primarily through the removal of residual luminal thrombus prior to restoration of flow; (ii) dual antiplatelet therapy with a single 75-mg dose of clopidogrel the night before surgery in addition to regular 75 mg aspirin which virtually abolished post-operative thromboembolic stroke and may also have contributed towards a decline in stroke/death following major cardiac events; and (iii) the provision of written guidance for managing post-CEA hypertension which was associated with virtual abolition of intracranial haemorrhage and stroke as a result of hyperperfusion syndrome." | 4.89 | Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy. ( Bell, PR; Bown, MJ; Dennis, MJ; London, NJ; McCarthy, MJ; Nasim, A; Naylor, AR; Sayers, RD, 2013) |
| "PubMed and MEDLINE searches (up to January 2010) were performed to identify primary literature, using search terms including aspirin, stroke prevention, acute ischemic stroke, acetylsalicylic acid, atrial fibrillation, myocardial infarction, and carotid endarterectomy." | 4.86 | Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. ( Ansara, AJ; Arif, SA; Koehler, JM; Nisly, SA; Nordmeyer, ST, 2010) |
| "End-pouch ECA aneurysms were created in adult rats and were then embedded with either platinum or HydroCoils." | 3.83 | Aspirin and Clopidogrel Inhibit Aneurysm Healing after HydroCoil Implantation in External Carotid Artery Aneurysm Model. ( Chaudhary, N; Gemmete, JJ; Li, P; Pandey, AS; Thompson, BG; Xi, G; Zhang, C, 2016) |
| "Recently developed interventional radiologic techniques, such as embolization with platinum coils, may induce thrombus formation within an aneurysm." | 3.70 | Detection of microemboli distal to cerebral aneurysms before and after therapeutic embolization. ( Berlit, P; Henkes, H; Klötzsch, C; Kühne, D; Nahser, HC, 1998) |
| "Further to characterize the processes involved in the FeCl3-induced thrombosis model, we determined the effect of aspirin, heparin, hirudin, trans-4-(aminomethyl) cyclohexane carboxylic acid (AMCHA), thrombocytopenia, and flow modifications on time to occlusion (TTO) and thrombus weight (TW) in the rat carotid artery." | 3.70 | Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. ( Kambayashi, J; Lockyer, S, 1999) |
| "Thromboxane A2 (TXA2) biosynthesis was studied in healthy subjects, patients with chronic cerebral infarction, patients under chronic aspirin treatment and patients with atrial fibrillation." | 3.68 | Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction. ( Hayashi, Y; Nakahama, H; Nakanishi, T; Shimizu, S; Sugita, M; Takiguchi, A; Uyama, O; Yamamoto, S, 1992) |
| "Data from the medical treatment group of the Aspirin in TIA study were reviewed, and prospective analysis of patients with asymptomatic bruits was performed to see whether carotid stenosis (0 to 49% or 50 to 99%) or ulceration produced an increased risk of ipsilateral TIA or infarct." | 3.67 | The significance of carotid stenosis or ulceration. ( Bigelow, RH; Fields, WS; Grotta, JC; Hankins, L; Hu, H, 1984) |
| "Patients with carotid atherosclerotic plaques were enrolled and randomly assigned (1:1) to receive either DZSM capsules or aspirin." | 3.11 | Dengzhan Shengmai capsule versus Aspirin in the treatment of carotid atherosclerotic plaque: A single-centre, non-inferiority, prospective, randomised controlled trial. ( Jin, J; Liu, Y; Qu, L; Shen, X; Wu, J; Zou, S, 2022) |
| "Methods- Carotid atherosclerosis was analyzed either as the presence of mild (ie, 20%-49%) atherosclerotic stenosis or, separately, as the presence of carotid plaque." | 2.90 | Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. ( Amarenco, P; Berkowitz, SD; Bornstein, N; Camps-Renom, P; Connolly, SJ; Cucchiara, B; Gagliardi, RJ; Hart, RG; Korompoki, E; Lang, W; Lavados, P; Makaritsis, K; Marti-Fabregas, J; Meseguer, E; Milionis, H; Mundl, H; Ntaios, G; Papavasileiou, V; Siegler, JE; Swaminathan, B; Vemmos, K, 2019) |
| "Aspirin response test was evaluated 1 hour after aspirin intake using multiplate platelet function analyzer, and carotid ultrasonography has been performed to determine carotid intima-media thickness (CIMT) and the presence of carotid plaque." | 2.87 | The Relationship Between Aspirin Resistance and Carotid Imaging in Young Patients With ST-Segment Elevated Myocardial Infarction: A Cross-Sectional Study. ( Bulut, U; Demir, AR; Kalayci, B; Karakurt, H; Karakurt, ST; Serbest, NG; Somuncu, MU, 2018) |
| "The aspirin effect was the same across all risk-factor groups." | 2.66 | Controlled trial of aspirin in cerebral ischemia: an addendum. ( Fields, WS; Gary, HE; Lemak, NA, 1986) |
| "Four patients presented transient ischemic attacks, one amaurosis fugax, two suffered from a minor stroke, four had non-focalized ischemic cerebral symptoms and two were asymptomatic." | 2.40 | Fibromuscular dysplasia of the internal carotid artery. Personal experience with 13 cases and literature review. ( Limet, R; Sakalihasan, N; Van Damme, H, 1999) |
| " Furthermore, in assessing the potential benefits of long-term use of ASA for prophylactic purposes in these patients, one should also evaluate the side-effects and intolerance related to its chronic use, as well as its potential complications especially from a gastrointestinal perspective." | 2.39 | Aspirin in asymptomatic carotid disease. ( Côté, R, 1994) |
| "In children and young adults, amaurosis fugax is a benign condition." | 2.38 | Atherosclerotic carotid disease and the eye. ( Breen, LA, 1991) |
| " Among the anti-aggregant agents, only Aspirin at high dosage (1 to 1." | 2.37 | [The fate of patients with carotid stenosis. Comparative study, based on the literature, of their natural history and evolution under medical treatment or following endarterectomy]. ( Bachet, P; Ninet, J; Pasquier, J, 1985) |
| "It is also helpful in patients with amaurosis fugax, and may benefit selected patients with acute stroke or those with asymptomatic but hemodynamically significant stenosis." | 2.37 | Carotid surgery in stroke prevention. ( Busuttil, RW; Sheng, FC, 1986) |
| "Aspirin treatment antagonized vascular stiffening and rivaroxaban treatment led to a positive trend towards reduced stiffening." | 1.56 | Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery. ( Brouns, AE; Chayoua, W; Coenen, DM; Cosemans, JMEM; Debets, J; Heitmeier, S; Karel, MFA; Konings, J; Korsten, EIJ; Kuijpers, MJE; Leenders, PJA; Mastenbroek, TG; Nagy, M; Spronk, HM; van Essen, H; van Oerle, R, 2020) |
| "Peripheral artery disease affects 1." | 1.51 | Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. ( Ademi, Z; Hird, TR; Liew, D; Owen, AJ; Reid, CM; Si, S; Tonkin, A; Zomer, E, 2019) |
| "Ischaemic stroke is a very uncommon, but severe complication of cisplatin-based chemotherapy." | 1.46 | Internal carotid artery occlusion and stroke as a complication of cisplatin-based chemotherapy for metastatic testicular germ cell tumour. ( Azam, M; Cerrud-Rodriguez, RC; Quinteros, MG, 2017) |
| "Takayasu arteritis was diagnosed subsequently." | 1.46 | Complete ophthalmoplegia, complete ptosis and dilated pupil due to internal carotid artery dissection: as the first manifestation of Takayasu arteritis. ( Herath, HMMTB; Pahalagamage, SP; Senanayake, S; Withana, D, 2017) |
| "Onyx HD-500 is a liquid embolic used to treat intracranial aneurysms." | 1.39 | Continued concern about parent vessel steno-occlusive progression with Onyx HD-500 and the utility of quantitative magnetic resonance imaging in serial assessment. ( Alaraj, A; Aletich, VA; Amin-Hanjani, S; Carlson, AP; Charbel, FT, 2013) |
| "Tuberous sclerosis is an autosomal dominant inherited phakomatosis." | 1.36 | [Tuberous sclerosis and intracranial aneurysms: a rare association]. ( Aissi, M; Boughammoura-Bouatay, A; Frih-Ayed, M; Jerbi-Ommezzine, S; Sfar, MH; Younes-Mhenni, S, 2010) |
| "Combined carotid stenting and cardiac surgery, performed in the same operating room under only heparin and aspirin, seems a safe and effective strategy for the treatment of patients with concomitant carotid and cardiac disease." | 1.35 | Safety and effectiveness of combining carotid artery stenting with cardiac surgery: preliminary results of a single-center experience. ( Capuano, F; Faraglia, V; Palombo, G; Rizzo, L; Sinatra, R; Stella, N; Taurino, M, 2009) |
| "He suffered immediate loss of consciousness but recovered three days later with right-sided hemiplegia and complete aphasia." | 1.34 | Carotid occlusion and cerebral infarction from camel bite: case report. ( Laseini, A; Mahmud, MR; Nasiru, JI; Saidu, SA; Shehu, BB, 2007) |
| "8 patients with 9 spontaneous dissecting aneurysms of the cervical carotid artery--5 of which were symptomatic--plus one patient with ofthalmoplegia due to an aneurysm of the cavernous carotid artery were studied." | 1.34 | [Treatment of carotid artery aneurysms with covered stents]. ( Alfke, K; Bartsch, T; Dörner, L; Jansen, O; Rohr, A; Stingele, R, 2007) |
| "A novel model to induce occlusive thrombus formation was developed in mice in vivo." | 1.32 | A novel model of occlusive thrombus formation in mice. ( Cheng, XW; Iguchi, A; Kanda, S; Koike, T; Kuzuya, M; Maeda, K; Nakamura, K; Sasaki, T; Sato, K; Tamaya-Mori, N, 2004) |
| "Aspirin treatment attenuated smoking-induced changes in plaque composition." | 1.31 | Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. ( Cercek, B; Chyu, KY; Dimayuga, P; Fishbein, MC; Kangavari, S; Matetzky, S; Shah, PK; Tani, S; Xu, H; Yano, J, 2000) |
| "Macrophage density in carotid artery plaques classified by B-mode ultrasound imaging as echolucent (n = 56), intermediate (n = 25), or echorich (n = 25) was 1." | 1.31 | Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. ( Bentzon, J; Falk, E; Grønholdt, ML; Nordestgaard, BG; Sillesen, H; Wiebe, BM; Zhou, J, 2002) |
| "The extent of carotid atherosclerosis was determined by real-time B-mode ultrasonography." | 1.29 | Risk factors for carotid atherosclerosis and platelet activation. ( Matsui, Y; Michishita, H; Shimizu, S; Sugita, M; Uyama, O, 1994) |
| "To determine whether anticoagulation practices have changed when heparin and warfarin are used to treat cerebrovascular disease, and to determine the dosage of aspirin used to treat carotid territory transient ischemic attacks (TIAs)." | 1.29 | A follow-up survey of clinical practices for the use of heparin, warfarin, and aspirin. ( Alberts, MJ; Dawson, DV; Massey, EW, 1994) |
| "However, their effects on thrombus formation have rarely been evaluated in experimental animals in vivo." | 1.29 | In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis. ( Iwamoto, Y; Naritomi, H; Nishimura, H; Sugita, M; Tachibana, H, 1996) |
| "Ticlopidine was more effective in patients without carotid stenosis." | 1.28 | Prevention of stroke with ticlopidine: who benefits most? TASS Baseline and Angiographic Data Subgroup. ( Grotta, JC; Kamm, B; Norris, JW, 1992) |
| "Eleven of these 21 patients had cerebral infarctions while taking aspirin, and 7 of these 11 infarcts occurred without the prior warning of transient ischemic attacks." | 1.28 | Patterns of failure of aspirin treatment in symptomatic atherosclerotic carotid artery disease. ( Chen, TL; Chyatte, D, 1990) |
| "The frequency of a high-grade restenosis in patients with diabetes mellitus and coronary heart disease was not significantly increased, but supports the view that these are risk factors in the development of atherosclerotic changes in an operated carotid artery." | 1.28 | Late carotid restenosis: aetiologic factors for recurrent carotid artery stenosis during long-term follow-up. ( Haapanen, A; Harju, E; Jokela, H; Riekkinen, H; Salenius, JP, 1989) |
| "Fibromuscular dysplasia is an arteriopathy of unknown etiology that affects the intermediate-size branches of the aorta." | 1.28 | Fibromuscular dysplasia of the carotid arteries complicating pregnancy. ( Beyth, Y; Ezra, Y; Kidron, D, 1989) |
| " Dose-response platelet aggregometry detected no differences between groups in the sensitivity of platelets to adenosine diphosphate (ADP), collagen, and epinephrine." | 1.27 | Etiologic factors for recurrent carotid artery stenosis. ( Clagett, GP; Hutton, JE; McDonald, PT; Olson, DW; Rich, NM; Salander, JM; Youkey, JR, 1983) |
| "A patient is reported who sustained a cerebral infarction from carotid artery disease and was treated with aspirin." | 1.27 | Aspirin, anticoagulants, and hemorrhagic conversion of ischemic infarction: hypothesis and implications. ( Fisher, M, 1986) |
| "In no patient did the thrombus progress to occlude the vessel completely, and no new distal emboli were identified on the follow-up angiograms." | 1.27 | Intraluminal thrombus of the internal carotid arteries: angiographic demonstration of resolution with anticoagulant therapy alone. ( Barnett, HJ; Buchan, A; Fox, AJ; Pelz, DM; Vinuela, F, 1986) |
| "Delayed ipsilateral carotid arteritis is a known complication of herpes zoster ophthalmicus." | 1.26 | Transient contralateral hemiplegia after ophthalmic zoster. Therapeutic problems in elderly patients. ( Calloni, MV; Landi, G; Scarlato, G, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 55 (34.81) | 18.7374 |
| 1990's | 35 (22.15) | 18.2507 |
| 2000's | 23 (14.56) | 29.6817 |
| 2010's | 37 (23.42) | 24.3611 |
| 2020's | 8 (5.06) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, X | 1 |
| Zou, S | 1 |
| Jin, J | 1 |
| Liu, Y | 1 |
| Wu, J | 1 |
| Qu, L | 1 |
| Ntaios, G | 1 |
| Swaminathan, B | 1 |
| Berkowitz, SD | 1 |
| Gagliardi, RJ | 1 |
| Lang, W | 1 |
| Siegler, JE | 1 |
| Lavados, P | 1 |
| Mundl, H | 1 |
| Bornstein, N | 1 |
| Meseguer, E | 1 |
| Amarenco, P | 1 |
| Cucchiara, B | 1 |
| Camps-Renom, P | 1 |
| Makaritsis, K | 1 |
| Korompoki, E | 1 |
| Papavasileiou, V | 1 |
| Marti-Fabregas, J | 1 |
| Milionis, H | 1 |
| Vemmos, K | 1 |
| Connolly, SJ | 2 |
| Hart, RG | 3 |
| Tirschwell, DL | 1 |
| Taylor, BL | 1 |
| Gresele, P | 1 |
| Paciullo, F | 1 |
| Migliacci, R | 1 |
| Ball, STE | 1 |
| Taylor, R | 1 |
| McCollum, CN | 2 |
| Bulwa, Z | 1 |
| Saleh Velez, FG | 1 |
| Brorson, JR | 1 |
| Pinto, CB | 1 |
| Mastenbroek, TG | 1 |
| Karel, MFA | 1 |
| Nagy, M | 1 |
| Chayoua, W | 1 |
| Korsten, EIJ | 1 |
| Coenen, DM | 1 |
| Debets, J | 1 |
| Konings, J | 1 |
| Brouns, AE | 1 |
| Leenders, PJA | 1 |
| van Essen, H | 1 |
| van Oerle, R | 1 |
| Heitmeier, S | 1 |
| Spronk, HM | 1 |
| Kuijpers, MJE | 1 |
| Cosemans, JMEM | 1 |
| Gao, M | 1 |
| Lei, J | 1 |
| Ho, JP | 1 |
| Galex, IA | 1 |
| Sadeghi, NB | 1 |
| Weledji, N | 1 |
| Cabello Bermudez, SI | 1 |
| Mitchell, BA | 1 |
| Bush, DM | 1 |
| Yap, E | 1 |
| Davis, NC | 1 |
| Catalino, MP | 1 |
| Godfrey, V | 1 |
| Nielsen, JN | 1 |
| Lee, YZ | 1 |
| Sasaki-Adams, DM | 1 |
| Policha, A | 1 |
| Williams, D | 1 |
| Adelman, M | 1 |
| Veith, F | 1 |
| Cayne, NS | 1 |
| Cerrud-Rodriguez, RC | 1 |
| Quinteros, MG | 1 |
| Azam, M | 1 |
| Herath, HMMTB | 1 |
| Pahalagamage, SP | 1 |
| Withana, D | 1 |
| Senanayake, S | 1 |
| Aboyans, V | 4 |
| Desormais, I | 1 |
| Jarlan, L | 1 |
| Teissier, MP | 1 |
| Lacroix, P | 1 |
| Anand, SS | 2 |
| Bosch, J | 2 |
| Eikelboom, JW | 2 |
| Diaz, R | 1 |
| Widimsky, P | 1 |
| Alings, M | 1 |
| Kakkar, AK | 1 |
| Keltai, K | 1 |
| Maggioni, AP | 1 |
| Lewis, BS | 1 |
| Störk, S | 1 |
| Zhu, J | 1 |
| Lopez-Jaramillo, P | 1 |
| O'Donnell, M | 1 |
| Commerford, PJ | 1 |
| Vinereanu, D | 1 |
| Pogosova, N | 1 |
| Ryden, L | 1 |
| Fox, KAA | 1 |
| Bhatt, DL | 1 |
| Misselwitz, F | 1 |
| Varigos, JD | 1 |
| Vanassche, T | 1 |
| Avezum, AA | 1 |
| Chen, E | 1 |
| Branch, K | 1 |
| Leong, DP | 1 |
| Bangdiwala, SI | 1 |
| Yusuf, S | 1 |
| Antigüedad-Muñoz, J | 1 |
| de la Riva, P | 1 |
| Arenaza Choperena, G | 1 |
| Muñoz Lopetegi, A | 1 |
| Andrés Marín, N | 1 |
| Fernández-Eulate, G | 1 |
| Moreno Valladares, M | 1 |
| Martínez Zabaleta, M | 1 |
| Mant, J | 1 |
| Li, W | 1 |
| Chen, Z | 1 |
| Dai, Z | 1 |
| Liu, R | 1 |
| Yin, Q | 1 |
| Wang, H | 1 |
| Hao, Y | 1 |
| Han, Y | 1 |
| Qiu, Z | 1 |
| Xiong, Y | 1 |
| Sun, W | 1 |
| Zi, W | 1 |
| Xu, G | 1 |
| Liu, X | 1 |
| Somuncu, MU | 1 |
| Demir, AR | 1 |
| Karakurt, H | 1 |
| Serbest, NG | 1 |
| Kalayci, B | 1 |
| Bulut, U | 1 |
| Karakurt, ST | 1 |
| Jha, N | 1 |
| Crockett, MT | 1 |
| Singh, TP | 1 |
| Cunningham, TK | 1 |
| Draper, H | 1 |
| Rajesh, U | 1 |
| Zomer, E | 1 |
| Si, S | 1 |
| Hird, TR | 1 |
| Liew, D | 1 |
| Owen, AJ | 1 |
| Tonkin, A | 1 |
| Reid, CM | 1 |
| Ademi, Z | 1 |
| Pastori, D | 1 |
| Patel, MR | 1 |
| Tanguay, JF | 1 |
| Ricco, JB | 1 |
| Debus, ES | 1 |
| Mazzolai, L | 2 |
| Bauersachs, R | 1 |
| Verhamme, P | 1 |
| Nikol, S | 1 |
| Nehler, M | 1 |
| Violi, F | 1 |
| Bender, MT | 1 |
| Zarrin, DA | 1 |
| Jiang, B | 1 |
| Campos, JK | 1 |
| Lin, LM | 1 |
| Young, RW | 1 |
| Colby, GP | 1 |
| Coon, AL | 1 |
| Naylor, AR | 2 |
| Sayers, RD | 1 |
| McCarthy, MJ | 1 |
| Bown, MJ | 1 |
| Nasim, A | 1 |
| Dennis, MJ | 1 |
| London, NJ | 1 |
| Bell, PR | 1 |
| Brown, MM | 1 |
| Chehab, BM | 1 |
| Gupta, K | 1 |
| Mendiz, OA | 1 |
| Fava, CM | 1 |
| Lev, GA | 1 |
| Valdivieso, LR | 1 |
| Caponi, G | 1 |
| Hidalgo Alava, GF | 1 |
| Favaloro, RR | 1 |
| Chalouhi, N | 1 |
| Zanaty, M | 1 |
| Tjoumakaris, S | 1 |
| Gonzalez, LF | 1 |
| Hasan, D | 1 |
| Kung, D | 1 |
| Rosenwasser, RH | 1 |
| Jabbour, P | 1 |
| Brodmann, M | 1 |
| De Carlo, M | 1 |
| Clement, D | 1 |
| van Bortel, L | 1 |
| van Sambeek, MR | 1 |
| Vlachopoulos, C | 1 |
| Jones, DW | 1 |
| Goodney, PP | 1 |
| Conrad, MF | 1 |
| Nolan, BW | 2 |
| Rzucidlo, EM | 1 |
| Powell, RJ | 1 |
| Cronenwett, JL | 1 |
| Stone, DH | 2 |
| Allende, M | 1 |
| Molina, E | 1 |
| Guruceaga, E | 1 |
| Tamayo, I | 1 |
| González-Porras, JR | 1 |
| Gonzalez-López, TJ | 1 |
| Toledo, E | 1 |
| Rabal, O | 1 |
| Ugarte, A | 1 |
| Roldán, V | 1 |
| Rivera, J | 1 |
| Oyarzabal, J | 1 |
| Montes, R | 1 |
| Hermida, J | 1 |
| Brenner, T | 1 |
| Schmitt, FC | 1 |
| Demirel, S | 1 |
| Salgado, E | 1 |
| Celi de la Torre, JA | 1 |
| Göring, M | 1 |
| Bruckner, T | 1 |
| Böckler, D | 1 |
| Weigand, MA | 1 |
| Hofer, S | 1 |
| Attigah, N | 1 |
| Zhang, C | 1 |
| Li, P | 1 |
| Xi, G | 1 |
| Gemmete, JJ | 1 |
| Chaudhary, N | 1 |
| Thompson, BG | 1 |
| Pandey, AS | 1 |
| Palombo, G | 1 |
| Stella, N | 1 |
| Faraglia, V | 1 |
| Rizzo, L | 1 |
| Capuano, F | 1 |
| Sinatra, R | 1 |
| Taurino, M | 1 |
| Wehinger, A | 1 |
| Tancevski, I | 1 |
| Seiler, R | 1 |
| Frotschnig, SM | 1 |
| Frantz, S | 1 |
| Huber, J | 1 |
| Eller, P | 1 |
| Schgoer, W | 1 |
| Foeger, B | 1 |
| Patsch, JR | 1 |
| Ritsch, A | 1 |
| McMahon, GS | 1 |
| Webster, SE | 1 |
| Hayes, PD | 1 |
| Jones, CI | 1 |
| Goodall, AH | 1 |
| Tautenhahn, J | 1 |
| Meyer, F | 1 |
| Pech, M | 1 |
| Michael, L | 1 |
| Goertler, M | 1 |
| Halloul, Z | 1 |
| Enomoto, Y | 1 |
| Adachi, S | 1 |
| Matsushima-Nishiwaki, R | 1 |
| Doi, T | 1 |
| Niwa, M | 1 |
| Akamatsu, S | 1 |
| Tokuda, H | 1 |
| Ogura, S | 1 |
| Yoshimura, S | 1 |
| Iwama, T | 1 |
| Kozawa, O | 1 |
| Daugherty, WP | 1 |
| Clarke, MJ | 1 |
| Cloft, HJ | 1 |
| Lanzino, GL | 1 |
| Ansara, AJ | 1 |
| Nisly, SA | 1 |
| Arif, SA | 1 |
| Koehler, JM | 1 |
| Nordmeyer, ST | 1 |
| Aissi, M | 1 |
| Younes-Mhenni, S | 1 |
| Jerbi-Ommezzine, S | 1 |
| Boughammoura-Bouatay, A | 1 |
| Frih-Ayed, M | 1 |
| Sfar, MH | 1 |
| Venker, C | 1 |
| Stracke, P | 1 |
| Berlit, P | 2 |
| Diehl, RR | 1 |
| Kurre, W | 1 |
| Sorgenfrei, U | 1 |
| Krämer, M | 1 |
| Chapot, R | 1 |
| Del Zotto, E | 1 |
| Ritelli, M | 1 |
| Pezzini, A | 1 |
| Drera, B | 1 |
| Gamba, M | 1 |
| Giossi, A | 1 |
| Volonghi, I | 1 |
| Costa, P | 1 |
| Barlati, S | 1 |
| Gasparotti, R | 1 |
| Padovani, A | 1 |
| Colombi, M | 1 |
| Jaberi, A | 1 |
| Lum, C | 1 |
| Stefanski, P | 1 |
| Thornhill, RE | 1 |
| Dowlatshahi, D | 1 |
| Chechik, O | 1 |
| Goldstein, Y | 1 |
| Behrbalk, E | 1 |
| Kaufman, E | 1 |
| Rabinovich, Y | 1 |
| Krishnan, M | 1 |
| Kumar, S | 1 |
| Ali, S | 1 |
| Iyer, RS | 1 |
| Fang, YB | 1 |
| Li, Q | 1 |
| Yang, PF | 1 |
| Huang, QH | 1 |
| Zhao, WY | 1 |
| Xu, Y | 1 |
| Hong, B | 1 |
| Liu, JM | 1 |
| Carlson, AP | 1 |
| Alaraj, A | 1 |
| Amin-Hanjani, S | 1 |
| Charbel, FT | 1 |
| Aletich, VA | 1 |
| Willeit, P | 1 |
| Zampetaki, A | 1 |
| Dudek, K | 1 |
| Kaudewitz, D | 1 |
| King, A | 1 |
| Kirkby, NS | 1 |
| Crosby-Nwaobi, R | 1 |
| Prokopi, M | 1 |
| Drozdov, I | 1 |
| Langley, SR | 1 |
| Sivaprasad, S | 1 |
| Markus, HS | 2 |
| Mitchell, JA | 1 |
| Warner, TD | 1 |
| Kiechl, S | 1 |
| Mayr, M | 1 |
| Junghans, U | 1 |
| Siebler, M | 1 |
| Barnett, HJ | 2 |
| Meldrum, H | 1 |
| Eliasziw, M | 1 |
| Ferguson, GG | 1 |
| Sasaki, T | 1 |
| Kuzuya, M | 1 |
| Cheng, XW | 1 |
| Nakamura, K | 1 |
| Tamaya-Mori, N | 1 |
| Maeda, K | 1 |
| Kanda, S | 1 |
| Koike, T | 1 |
| Sato, K | 1 |
| Iguchi, A | 1 |
| Conforto, AB | 1 |
| Puglia, P | 1 |
| Yamamoto, FI | 1 |
| Scaff, M | 1 |
| Inoue, A | 1 |
| Fukumoto, SY | 1 |
| Kumon, Y | 1 |
| Watanabe, H | 1 |
| Fumoto, N | 1 |
| Oda, S | 1 |
| Ohue, S | 1 |
| Ohnishi, T | 1 |
| Wang, X | 1 |
| Cheng, Q | 1 |
| Xu, L | 1 |
| Feuerstein, GZ | 1 |
| Hsu, MY | 1 |
| Smith, PL | 1 |
| Seiffert, DA | 1 |
| Schumacher, WA | 1 |
| Ogletree, ML | 1 |
| Gailani, D | 1 |
| Ballotta, E | 2 |
| Thiene, G | 2 |
| Baracchini, C | 1 |
| Ermani, M | 1 |
| Militello, C | 1 |
| Da Giau, G | 1 |
| Barbon, B | 1 |
| Angelini, A | 2 |
| Montalto, M | 1 |
| Curigliano, V | 1 |
| Santoro, L | 1 |
| Lombardi, M | 1 |
| Covino, M | 1 |
| Cammarota, G | 1 |
| Dalvai, S | 1 |
| D'Onofrio, F | 1 |
| Gasbarrini, A | 1 |
| Gasbarrini, G | 1 |
| Faggioli, GL | 1 |
| Ferri, M | 1 |
| Rossi, C | 1 |
| Gargiulo, M | 1 |
| Freyrie, A | 1 |
| Stella, A | 1 |
| Huang, R | 1 |
| Patel, RB | 1 |
| Ma, H | 1 |
| Taylor, K | 1 |
| Abela, GS | 1 |
| Rohr, A | 1 |
| Alfke, K | 1 |
| Dörner, L | 1 |
| Bartsch, T | 1 |
| Stingele, R | 1 |
| Jansen, O | 1 |
| Weinberger, J | 1 |
| Shehu, BB | 1 |
| Nasiru, JI | 1 |
| Mahmud, MR | 1 |
| Laseini, A | 1 |
| Saidu, SA | 1 |
| Landi, G | 1 |
| Calloni, MV | 1 |
| Scarlato, G | 1 |
| Bastard, J | 1 |
| Goas, JY | 1 |
| Born, GV | 1 |
| Görög, P | 1 |
| Begent, NA | 1 |
| Kistler, JP | 1 |
| Ropper, AH | 1 |
| Heros, RC | 1 |
| Clagett, GP | 2 |
| Youkey, JR | 2 |
| Brigham, RA | 1 |
| Orecchia, PM | 1 |
| Salander, JM | 2 |
| Collins, GJ | 1 |
| Rich, NM | 2 |
| Cain, TD | 1 |
| Wood, JS | 1 |
| Beard, OW | 1 |
| Rushton, FW | 1 |
| Kukora, JS | 1 |
| Grotta, JC | 2 |
| Bigelow, RH | 1 |
| Hu, H | 1 |
| Hankins, L | 1 |
| Fields, WS | 4 |
| Donaldson, IM | 1 |
| Bouchier-Hayes, D | 1 |
| Whisnant, JP | 2 |
| McDonald, PT | 1 |
| Olson, DW | 1 |
| Hutton, JE | 1 |
| Mustard, JF | 1 |
| Packham, MA | 1 |
| Kinlough-Rathbone, RL | 1 |
| Laiwah, AC | 1 |
| Dujovny, M | 1 |
| Kossovsky, N | 1 |
| Loubeau, JM | 1 |
| Nelson, D | 1 |
| McManus, G | 1 |
| Nair, KK | 1 |
| Carson, SN | 1 |
| Demling, RH | 1 |
| Esquivel, CO | 1 |
| Levin, SM | 1 |
| Sondheimer, FK | 1 |
| Levin, JM | 1 |
| Eriksson, SE | 1 |
| Côté, R | 1 |
| Uyama, O | 2 |
| Matsui, Y | 1 |
| Shimizu, S | 2 |
| Michishita, H | 1 |
| Sugita, M | 3 |
| Alberts, MJ | 1 |
| Dawson, DV | 1 |
| Massey, EW | 1 |
| McCann, RL | 1 |
| Ranke, C | 1 |
| Hecker, H | 1 |
| Creutzig, A | 1 |
| Alexander, K | 1 |
| Nishimura, H | 1 |
| Naritomi, H | 1 |
| Iwamoto, Y | 1 |
| Tachibana, H | 1 |
| Sivaguru, A | 1 |
| Venables, GS | 1 |
| Beard, JD | 1 |
| Gaines, PA | 1 |
| Diethrich, EB | 1 |
| Ndiaye, M | 1 |
| Reid, DB | 1 |
| Abbruzzese, E | 1 |
| Bottio, T | 1 |
| Dagiau, G | 1 |
| Saladini, M | 1 |
| Israsena, N | 1 |
| Phanthumchinda, K | 1 |
| Sinsawaiwong, S | 1 |
| Lerdlum, S | 1 |
| Eachempati, SR | 1 |
| Sebastian, MW | 1 |
| Reed, RL | 1 |
| Calvey, TA | 1 |
| Gough, MJ | 1 |
| González-Gay, MA | 1 |
| García-Porrúa, C | 1 |
| Brañas, F | 1 |
| Klötzsch, C | 1 |
| Nahser, HC | 1 |
| Henkes, H | 1 |
| Kühne, D | 1 |
| Riggs, PN | 1 |
| DeWeese, JA | 1 |
| Lockyer, S | 1 |
| Kambayashi, J | 1 |
| Cesarone, MR | 1 |
| Laurora, G | 1 |
| DeSanctis, MT | 1 |
| Incandela, L | 1 |
| Fugazza, L | 1 |
| Girardello, R | 1 |
| Poli, A | 1 |
| Peracino, L | 1 |
| Ambrosoli, L | 1 |
| Belcaro, G | 1 |
| Van Damme, H | 1 |
| Sakalihasan, N | 1 |
| Limet, R | 1 |
| Albers, GW | 1 |
| Lutsep, HL | 1 |
| Newell, DW | 1 |
| Sacco, RL | 1 |
| Matetzky, S | 1 |
| Tani, S | 1 |
| Kangavari, S | 1 |
| Dimayuga, P | 1 |
| Yano, J | 1 |
| Xu, H | 1 |
| Chyu, KY | 1 |
| Fishbein, MC | 1 |
| Shah, PK | 1 |
| Cercek, B | 1 |
| Stemme, V | 1 |
| Swedenborg, J | 1 |
| Claesson, H | 1 |
| Hansson, GK | 1 |
| Greenland, P | 1 |
| Smith, SC | 1 |
| Grundy, SM | 1 |
| Grønholdt, ML | 1 |
| Nordestgaard, BG | 1 |
| Bentzon, J | 1 |
| Wiebe, BM | 1 |
| Zhou, J | 1 |
| Falk, E | 1 |
| Sillesen, H | 1 |
| Kaposzta, Z | 1 |
| Martin, JF | 1 |
| Lunev, DK | 1 |
| Romasenko, MV | 1 |
| Kniazeva, GR | 1 |
| Kutchak, EN | 1 |
| Bragina, LK | 1 |
| Gertz, SD | 1 |
| Kurgan, A | 1 |
| Wajnberg, RS | 1 |
| Nelson, E | 1 |
| Duncan, GW | 1 |
| Pessin, MS | 1 |
| Mohr, JP | 2 |
| Adams, RD | 1 |
| Nakanishi, T | 1 |
| Nakahama, H | 1 |
| Takiguchi, A | 1 |
| Hayashi, Y | 1 |
| Yamamoto, S | 1 |
| Schulze, HE | 1 |
| Ebner, A | 1 |
| Besinger, UA | 1 |
| Norris, JW | 1 |
| Kamm, B | 1 |
| Foster, RE | 1 |
| Kosmorsky, GS | 1 |
| Sweeney, PJ | 1 |
| Masaryk, TJ | 1 |
| Breen, LA | 1 |
| Diener, HC | 1 |
| Loherstorfer, E | 1 |
| Seboldt, H | 1 |
| Dichgans, J | 1 |
| Widder, B | 1 |
| Kleiser, B | 1 |
| Krapf, H | 1 |
| Reuchlin, G | 1 |
| Dürr, A | 1 |
| Pramsohler, B | 1 |
| Lupattelli, G | 1 |
| Scholz, H | 1 |
| Sinzinger, H | 1 |
| Kretschmer, G | 3 |
| Pratschner, T | 2 |
| Prager, M | 2 |
| Wenzl, E | 2 |
| Polterauer, P | 2 |
| Schemper, M | 1 |
| Ehringer, H | 3 |
| Minar, E | 2 |
| Horvath, R | 1 |
| Holzner, H | 1 |
| Völker, W | 1 |
| Faber, V | 1 |
| Chyatte, D | 1 |
| Chen, TL | 1 |
| Wade, J | 1 |
| Hobson, RW | 2 |
| Towne, J | 1 |
| Ezra, Y | 1 |
| Kidron, D | 1 |
| Beyth, Y | 1 |
| Salenius, JP | 1 |
| Haapanen, A | 1 |
| Harju, E | 1 |
| Jokela, H | 1 |
| Riekkinen, H | 1 |
| Yeager, RA | 1 |
| Moneta, GL | 1 |
| McConnell, DB | 1 |
| Neuwelt, EA | 1 |
| Taylor, LM | 1 |
| Porter, JM | 1 |
| Corbeel, L | 1 |
| Gewillig, M | 1 |
| Baeten, E | 1 |
| Casteels-Van Daele, M | 1 |
| Eggermont, E | 1 |
| Dudczak, R | 1 |
| Schöfl, R | 1 |
| Jung, M | 1 |
| Koppensteiner, R | 1 |
| Ahmadi, R | 1 |
| Wiebers, DO | 1 |
| Swanson, JW | 1 |
| Cascino, TL | 1 |
| Lam, JY | 1 |
| Chesebro, JH | 1 |
| Steele, PM | 1 |
| Badimon, L | 1 |
| Fuster, V | 1 |
| Scheinberg, P | 1 |
| Callow, AD | 1 |
| Caplan, LR | 1 |
| Correll, JW | 1 |
| Moore, WS | 1 |
| Robertson, JT | 1 |
| Toole, JF | 1 |
| Patterson, RH | 1 |
| Gilligan, BS | 1 |
| Kassirer, JP | 1 |
| Kopelman, RI | 1 |
| Meek, AC | 1 |
| Chidlow, A | 1 |
| Lane, IF | 1 |
| Greenhalgh, RM | 1 |
| Becker, WL | 1 |
| Burde, RM | 1 |
| Fisher, M | 1 |
| Sheng, FC | 1 |
| Busuttil, RW | 1 |
| Lemak, NA | 1 |
| Gary, HE | 1 |
| Freeman, JW | 1 |
| Tuhrim, S | 1 |
| Reggia, JA | 1 |
| Rosenthal, D | 1 |
| Lamis, PA | 1 |
| Stanton, PE | 1 |
| Clark, MD | 1 |
| Ellison, RG | 1 |
| Pelz, DM | 1 |
| Buchan, A | 1 |
| Fox, AJ | 1 |
| Vinuela, F | 1 |
| Geeraert, AJ | 1 |
| Al Saigh, AH | 1 |
| Long, JB | 1 |
| Lynch, TG | 1 |
| Karanfilian, RG | 1 |
| Ninet, J | 1 |
| Bachet, P | 1 |
| Pasquier, J | 1 |
| Findlay, JM | 1 |
| Lougheed, WM | 1 |
| Gentili, F | 1 |
| Walker, PM | 1 |
| Glynn, MF | 1 |
| Houle, S | 1 |
| Wolf, PA | 1 |
| Bunt, TJ | 1 |
| Haynes, JL | 1 |
| Rubin, JR | 1 |
| Goldstone, J | 1 |
| Vroom, FQ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS),[NCT02313909] | Phase 3 | 7,213 participants (Actual) | Interventional | 2014-12-23 | Terminated (stopped due to Study halted early due to no efficacy improvement over aspirin at an interim analysis and very little chance of showing overall benefit if study were completed) | ||
| Platelet Function and Neurological Events Following Carotid Thromboendarterectomy[NCT05572320] | 386 participants (Anticipated) | Observational | 2022-10-10 | Recruiting | |||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.[NCT04218656] | Phase 4 | 159 participants (Actual) | Interventional | 2020-06-08 | Completed | ||
| Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion: A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial[NCT05902000] | 222 participants (Anticipated) | Interventional | 2023-06-14 | Recruiting | |||
| Prospective Evaluation for Hybrid Cardiac Procedures[NCT05143671] | 111 participants (Anticipated) | Observational | 2021-05-13 | Recruiting | |||
| A Prospective, Nonrandomized, Study Comparing the Use of Aspirin and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.[NCT02084615] | 300 participants (Anticipated) | Interventional | 2014-08-31 | Enrolling by invitation | |||
| The Characterisation of Vascular Biomarkers Before and After Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure and Their Role in Predicting Response[NCT02541773] | 58 participants (Anticipated) | Observational | 2013-11-30 | Active, not recruiting | |||
| Evaluation of Neurological Outcome in Patients Undergoing Cerebral Angiography and Revascularization Using Angioplasty and Stent-Supported Angioplasty[NCT00597974] | 108 participants (Actual) | Observational | 2003-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Major bleeding event (as per ISTH), defined as bleeding event that met at least one of following: fatal bleeding; symptomatic bleeding in a critical area or organ (intraarticular, intramuscular with compartment syndrome, intraocular, intraspinal, pericardial, or retroperitoneal); symptomatic intracranial haemorrhage; clinically overt bleeding associated with a recent decrease in the hemoglobin level of greater than or equal to (>=) 2 grams per decilitre (g/dL) (20 grams per liter [g/L]; 1.24 millimoles per liter [mmol/L]) compared to the most recent hemoglobin value available before the event; clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. The results were based on classification of events that have been positively adjudicated as major bleeding events. Incidence rate estimated as number of subjects with incident events divided by cumulative at-risk time, where subject is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.82 |
| Acetylsalicylic Acid 100 mg OD | 0.67 |
All-cause mortality includes all deaths of participants due to any cause. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.88 |
| Acetylsalicylic Acid 100 mg OD | 1.50 |
Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. Cardiovascular death includes death due to hemorrhage and death with undetermined/unknown cause. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms. The diagnosis of myocardial infarction requires the combination of: 1)evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and 2)supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 6.20 |
| Acetylsalicylic Acid 100 mg OD | 5.85 |
Non-major clinically relevant bleeding was defined as non-major overt bleeding but required medical attention (example: hospitalization, medical treatment for bleeding), and/or was associated with the study drug interruption of more than 14 days. The results were based on the outcome events at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 3.52 |
| Acetylsalicylic Acid 100 mg OD | 2.32 |
Intracranial hemorrhage included all bleeding events that occurred in intracerebral, sub arachnoidal as well as subdural or epidural sites. The below table displays results for all randomized participants and the outcomes at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 0.70 |
| Acetylsalicylic Acid 100 mg OD | 0.35 |
Life-threatening bleeding was defined as a subset of major bleeding that met at least one of the following criteria: 1) fatal bleeding; 2) symptomatic intracranial haemorrhage; 3) reduction in hemoglobin of at least 5 g/dl (50 g/l; 3.10 mmol/L); 4) transfusion of at least 4 units of packed red cells or whole blood; 5) associated with hypotension requiring the use of intravenous inotropic agents; 6) necessitated surgical intervention. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.02 |
| Acetylsalicylic Acid 100 mg OD | 0.43 |
Components of composite efficacy outcome (adjudicated) includes stroke (ischemic, hemorrhagic, and undefined stroke, TIA with positive neuroimaging) and systemic embolism. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 5.14 |
| Acetylsalicylic Acid 100 mg OD | 4.78 |
"Disabling stroke is defined as stroke with modified Rankin score (mRS) greater than or equal to (>=) 4 as assessed by investigator. mRS spans 0-6, running from perfect health to death. A score of 0-3 indicates functional status ranging from no symptoms to moderate disability (defined in the mRS as requiring some help, but able to walk without assistance); mRS 4-6 indicates functional status ranging from moderately severe disability (unable to walk or to attend to own bodily needs without assistance)through to death. CV death includes death due to hemorrhage and death with undetermined/unknown cause. Diagnosis of myocardial infarction requires combination of: 1) evidence of myocardial necrosis either changes in cardiac biomarkers or post-mortem pathological findings); 2) supporting information derived from clinical presentation, electrocardiographic changes, or results of myocardial or coronary artery imaging." (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) | ||||
|---|---|---|---|---|---|
| Stroke | Ischemic stroke | Disabling stroke | CV death(includes death due to hemorrhage) | Myocardial infarction | |
| Acetylsalicylic Acid 100 mg OD | 4.71 | 4.56 | 0.84 | 0.66 | 0.67 |
| Rivaroxaban 15 mg OD | 5.11 | 4.71 | 1.20 | 0.99 | 0.49 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
29 reviews available for aspirin and Carotid Artery Diseases
| Article | Year |
|---|---|
Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma.
Topics: Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Cerebrovascular Disorders; Fibrinolytic A | 2020 |
Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding.
Topics: Aspirin; Carotid Artery Diseases; Double-Blind Method; Hemorrhage; Humans; Rivaroxaban | 2018 |
Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy.
Topics: Aged; Anticoagulants; Aspirin; Atherosclerosis; Cardiology; Cardiovascular Diseases; Carotid Arterie | 2019 |
Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy.
Topics: Angioscopy; Aspirin; Carotid Artery Diseases; Clinical Protocols; Clopidogrel; Drug Therapy, Combina | 2013 |
Aggressive medical therapy alone is not adequate in certain patients with severe symptomatic carotid stenosis.
Topics: Aspirin; Atorvastatin; Carotid Artery Diseases; Clopidogrel; Constriction, Pathologic; Endovascular | 2013 |
Contemporary diagnosis of carotid fibromuscular dysplasia: role of power Doppler and a review of other diagnostic modalities.
Topics: Aspirin; Cardiovascular Agents; Carotid Artery Diseases; Female; Fibromuscular Dysplasia; Humans; Ma | 2013 |
The year in cardiology 2014: peripheral circulation.
Topics: Anticoagulants; Aortic Aneurysm, Abdominal; Aspirin; Biomarkers; Carotid Artery Diseases; Endovascul | 2015 |
Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature.
Topics: Aspirin; Atherosclerosis; Carotid Artery Diseases; Dose-Response Relationship, Drug; Endothelium, Va | 2010 |
Treatment of symptomatic arteriosclerotic carotid artery disease.
Topics: Aspirin; Carotid Artery Diseases; Cerebral Angiography; Clinical Trials as Topic; Endarterectomy, Ca | 2003 |
[Management of transient ischemic cerebral attacks (author's transl)].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Cerebral Revascularization; Enda | 1982 |
The biologic background to some therapeutic uses of aspirin.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Coronary Disease; Humans; In | 1983 |
Therapy of ischemic cerebral vascular disease due to atherothrombosis. (2).
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Auscultation; Basilar Artery; Blood Platelets; | 1984 |
Medical Grand Rounds: extracranial carotid artery disease.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Auscultation; Carotid Art | 1980 |
Aspirin in asymptomatic carotid disease.
Topics: Aspirin; Brain Ischemia; Carotid Artery Diseases; Carotid Stenosis; Cerebrovascular Disorders; Human | 1994 |
Surgical management of carotid artery atherosclerotic disease.
Topics: Aged; Angiography; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Cause of Death; Cerebrovascul | 1993 |
Posttraumatic bilateral carotid artery and right vertebral artery dissections in a patient with fibromuscular dysplasia: case report and review of the literature.
Topics: Accidents, Traffic; Adult; Aortic Dissection; Aspirin; Carotid Artery Diseases; Female; Fibromuscula | 1998 |
Carotid endarterectomy.
Topics: Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Pressure; Car | 1998 |
Fibromuscular dysplasia of the internal carotid artery. Personal experience with 13 cases and literature review.
Topics: Aged; Aneurysm; Angioplasty, Balloon; Aspirin; Blindness; Brain Ischemia; Carotid Artery Diseases; C | 1999 |
[Role of arterio-arterial embolisms in the pathogenesis of cerebral circulatory disorders].
Topics: Adult; Aged; Aspirin; Basilar Artery; Blood Coagulation; Carotid Arteries; Carotid Artery Diseases; | 1978 |
Transient cerebral ischemic attacks.
Topics: Anticoagulants; Arrhythmias, Cardiac; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blindn | 1976 |
Atherosclerotic carotid disease and the eye.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blindness; Carotid Artery Diseas | 1991 |
Current management of amaurosis fugax. The Amaurosis Fugax Study Group.
Topics: Aspirin; Blindness; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders; Constricti | 1990 |
Controversies in the management of cerebral vascular disease.
Topics: Aspirin; Atrial Fibrillation; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders; | 1988 |
Stroke. An overview.
Topics: Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Endarterectom | 1988 |
Transient ischaemic attacks: controversies in treatment. A review.
Topics: Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Endarterectomy; Humans; Ischemic Atta | 1988 |
Carotid surgery in stroke prevention.
Topics: Aged; Arteriosclerosis; Aspirin; Blindness; Carotid Arteries; Carotid Artery Diseases; Cerebrovascul | 1986 |
The management of TIAs in 1986.
Topics: Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Dipyridamo | 1986 |
Asymptomatic carotid disease.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disor | 1985 |
[The fate of patients with carotid stenosis. Comparative study, based on the literature, of their natural history and evolution under medical treatment or following endarterectomy].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Brain Ischemia; Carotid Artery Diseases; Combined Modalit | 1985 |
26 trials available for aspirin and Carotid Artery Diseases
| Article | Year |
|---|---|
Dengzhan Shengmai capsule versus Aspirin in the treatment of carotid atherosclerotic plaque: A single-centre, non-inferiority, prospective, randomised controlled trial.
Topics: Aspirin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Drugs, Chinese H | 2022 |
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Artery Diseases; | 2019 |
Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial.
Topics: Aged; Aspirin; Carotid Artery Diseases; Clopidogrel; Comorbidity; Double-Blind Method; Dual Anti-Pla | 2020 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
The Relationship Between Aspirin Resistance and Carotid Imaging in Young Patients With ST-Segment Elevated Myocardial Infarction: A Cross-Sectional Study.
Topics: Adult; Aspirin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Drug Resistance; Female; Hu | 2018 |
Aggressive medical therapy alone is not adequate in certain patients with severe symptomatic carotid stenosis.
Topics: Aspirin; Atorvastatin; Carotid Artery Diseases; Clopidogrel; Constriction, Pathologic; Endovascular | 2013 |
Low molecular weight heparin significantly reduces embolisation after carotid endarterectomy--a randomised controlled trial.
Topics: Adenosine Diphosphate; Aged; Anticoagulants; Arachidonic Acid; Aspirin; Carotid Artery Diseases; Dal | 2009 |
Cerebral microembolism is blocked by tirofiban, a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery Diseases; Clopidogrel; Female; Humans; Infus | 2003 |
Surgical vs medical treatment for isolated internal carotid artery elongation with coiling or kinking in symptomatic patients: a prospective randomized clinical study.
Topics: Aged; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Female; Fibrinolytic Agents; Follo | 2005 |
Asymptomatic cervical bruit and abnormal ocular pneumoplethysmography: a prospective study comparing two approaches to management.
Topics: Aged; Angiography; Arterial Occlusive Diseases; Aspirin; Auscultation; Carotid Arteries; Carotid Art | 1984 |
Medical Grand Rounds: extracranial carotid artery disease.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Auscultation; Carotid Art | 1980 |
Dose-dependent effect of aspirin on carotid atherosclerosis.
Topics: Aspirin; Carotid Artery Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hum | 1993 |
European carotid angioplasty trial.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Carotid Artery, | 1996 |
The elongation of the internal carotid artery: early and long-term results of patients having surgery compared with unoperated controls.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebrov | 1997 |
Effects of triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Arteriosclerosis; Aspirin; Carotid Artery D | 1999 |
Switching off embolization from symptomatic carotid plaque using S-nitrosoglutathione.
Topics: Aged; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Double-Blind Method; Female; Follo | 2002 |
Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group.
Topics: Aspirin; Auscultation; Carotid Artery Diseases; Cerebrovascular Disorders; Follow-Up Studies; Humans | 1991 |
Antiplatelet treatment prolongs survival after carotid bifurcation endarterectomy. Analysis of the clinical series followed by a controlled trial.
Topics: Aspirin; Carotid Artery Diseases; Coronary Disease; Endarterectomy; Female; Follow-Up Studies; Human | 1990 |
Antiplatelet therapy following carotid bifurcation endarterectomy. Evaluation of a controlled clinical trial. Prognostic significance of histologic plaque examination on behalf of survival.
Topics: Aged; Aspirin; Carotid Arteries; Carotid Artery Diseases; Endarterectomy; Female; Follow-Up Studies; | 1990 |
European Stroke Prevention Study. ESPS Group.
Topics: Age Factors; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical T | 1990 |
Effectiveness of carotid endarterectomy for asymptomatic carotid stenosis: design of a clinical trial. Mayo Asymptomatic Carotid Endarterectomy Study Group.
Topics: Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders; Constriction, Patholo | 1989 |
Carotid endarterectomy: what is its current status?
Topics: Arteriosclerosis; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders; Cli | 1988 |
Stroke. An overview.
Topics: Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Endarterectom | 1988 |
Controlled trial of aspirin in cerebral ischemia: an addendum.
Topics: Aspirin; Blindness; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Di | 1986 |
Asymptomatic carotid disease.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disor | 1985 |
Effect of perioperative platelet inhibition on postcarotid endarterectomy mural thrombus formation. Results of a prospective randomized controlled trial using aspirin and dipyridamole in humans.
Topics: Aged; Aspirin; Blood Platelets; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders | 1985 |
107 other studies available for aspirin and Carotid Artery Diseases
| Article | Year |
|---|---|
Is Embolic Stroke of Undetermined Source Shrinking?
Topics: Aspirin; Carotid Artery Diseases; Embolism; Humans; Rivaroxaban; Stroke | 2019 |
Resistance to Antiplatelet Therapy Is Associated With Symptoms of Cerebral Ischemia in Carotid Artery Disease.
Topics: Aspirin; Carotid Artery Diseases; Clopidogrel; Drug Resistance; Female; Humans; Infarction, Middle C | 2020 |
Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery.
Topics: Animals; Arteries; Aspirin; Blood Platelets; Carotid Arteries; Carotid Artery Diseases; Carotid Inti | 2020 |
Image and clinical analysis of common carotid web: a case report.
Topics: Aged; Anticoagulants; Aspirin; Basal Ganglia Diseases; Carotid Artery Diseases; Carotid Artery, Comm | 2021 |
Rabbit Elastase Aneurysm: Imaging and Histology Correlates for Inflammation and Healing.
Topics: Animals; Aspirin; Carotid Artery Diseases; Carotid Artery, Common; Disease Models, Animal; Disease P | 2021 |
Idiopathic Carotidynia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Flow Velocity; Carotid Artery Diseases; Caro | 2017 |
Internal carotid artery occlusion and stroke as a complication of cisplatin-based chemotherapy for metastatic testicular germ cell tumour.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspi | 2017 |
Complete ophthalmoplegia, complete ptosis and dilated pupil due to internal carotid artery dissection: as the first manifestation of Takayasu arteritis.
Topics: Adult; Angiography, Digital Subtraction; Aortic Dissection; Aspirin; Blepharoptosis; Carotid Artery | 2017 |
V. Aboyans et al. in response to the article by M. Helfre et al.: Usefulness of a systematic screening of carotid atherosclerosis in asymptomatic people with type 2 diabetes for cardiovascular risk reclassification. Ann Endocrinol (Paris). 2017;78:14-19.
Topics: Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Humans; Risk F | 2017 |
Internal Carotid Artery Web as the Cause of Recurrent Cryptogenic Ischemic Stroke.
Topics: Adult; Aspirin; Atorvastatin; Biopsy; Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases | 2018 |
Management of acute tandem occlusions: Stent-retriever thrombectomy with emergency stenting or angioplasty.
Topics: Aged; Angioplasty; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cl | 2018 |
Unusual right internal carotid artery supraclinoid segment fenestration associated with multiple aneurysms treated with flow diversion and coiling.
Topics: Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Clopidogrel; Endovascular Procedures; Fe | 2018 |
Management of a pregnancy with underlying fibromuscular dysplasia with a history of stroke and carotid artery dissection.
Topics: Adult; Aortic Dissection; Aspirin; Carotid Artery Diseases; Female; Fibromuscular Dysplasia; Humans; | 2019 |
Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
Topics: Aged; Aspirin; Australia; Carotid Artery Diseases; Cost-Benefit Analysis; Decision Support Technique | 2019 |
Aspirin Monotherapy in Flow Diversion of Selected Internal Carotid Artery Aneurysms.
Topics: Angiography, Digital Subtraction; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebr | 2020 |
Hybrid strategy for unstable patients with severe carotid and cardiac disease requiring surgery.
Topics: Aged; Angioplasty, Balloon; Anticoagulants; Aspirin; Cardiac Surgical Procedures; Carotid Artery Dis | 2015 |
Treatment of blister-like aneurysms with the pipeline embolization device.
Topics: Adult; Aged; Aged, 80 and over; Aneurysm, Ruptured; Angioplasty; Aspirin; Basilar Artery; Carotid Ar | 2014 |
Dual antiplatelet therapy reduces stroke but increases bleeding at the time of carotid endarterectomy.
Topics: Aged; Aspirin; Asymptomatic Diseases; Carotid Artery Diseases; Chi-Square Distribution; Clopidogrel; | 2016 |
Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk.
Topics: Animals; Aspirin; Atrial Fibrillation; Bleeding Time; Carotid Artery Diseases; Case-Control Studies; | 2016 |
The role of unfractionated heparin for the antiaggregatory effect of aspirin in patients undergoing carotid endarterectomy: Results of an observational clinical study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation; Blood Coagulation Tests; Caroti | 2017 |
Aspirin and Clopidogrel Inhibit Aneurysm Healing after HydroCoil Implantation in External Carotid Artery Aneurysm Model.
Topics: Aneurysm; Animals; Aspirin; Carotid Artery Diseases; Carotid Artery, External; Cell Movement; Clopid | 2016 |
Safety and effectiveness of combining carotid artery stenting with cardiac surgery: preliminary results of a single-center experience.
Topics: Aged; Aged, 80 and over; Angioplasty; Anticoagulants; Aspirin; Carotid Artery Diseases; Coronary Art | 2009 |
Influence of aspirin on SR-BI expression in human carotid plaques.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aspirin; Atherosclerosis; Carotid | 2009 |
[Diagnostics and treatment of carotidynia--rare angiological disease].
Topics: Angiography; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Artery Diseases; Carotid Arte | 2009 |
Thromboxane A(2) promotes soluble CD40 ligand release from human platelets.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aged; Aspirin; Atherosclerosis; | 2010 |
Going viral: fusiform vertebrobasilar and internal carotid aneurysms with varicella angiitis and common variable immunodeficiency.
Topics: Acyclovir; Adolescent; Aneurysm; Angiography, Digital Subtraction; Antiviral Agents; Aspirin; Basila | 2009 |
Comment on "variations in the pharmacological management of patients treated with carotid endarterectomy: a survey of European vascular surgeons".
Topics: Aspirin; Carotid Artery Diseases; Clopidogrel; Endarterectomy, Carotid; Europe; Humans; Incidence; P | 2010 |
[Tuberous sclerosis and intracranial aneurysms: a rare association].
Topics: Adult; Anticonvulsants; Aspirin; Carbamazepine; Carotid Artery Diseases; Humans; Intracranial Aneury | 2010 |
[New options in the therapeutic management of acute ischaemic stroke. Good results with combined i. v. and i. a. lysis and mechanical thrombectomy].
Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebral Angiography; | 2010 |
Clinical, neuroradiological and molecular features of a patient affected by pseudoxhantoma elasticum associated to carotid rete mirabile: case report.
Topics: Adult; Angiography, Digital Subtraction; Aspirin; Brain Ischemia; Carotid Arteries; Carotid Artery D | 2012 |
Computed tomography angiography evaluation of internal carotid artery free-floating thrombus--single-center diagnosis, false-positives, and follow-up.
Topics: Aged; Anticoagulants; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Clopidogrel; Diagn | 2012 |
Blood loss and complications following carotid endarterectomy in patients treated with clopidogrel.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carotid Artery Diseases; Clopidogrel; Drug T | 2012 |
Sudden bilateral anterior cerebral infarction: unusual stroke associated with unusual vascular anomalies.
Topics: Adult; Aspirin; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Internal; Drug Therapy, Combi | 2013 |
Treatment of blood blister-like aneurysms of the internal carotid artery with stent-assisted coil embolization.
Topics: Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral Angiography; Clopidogrel; Embol | 2013 |
Continued concern about parent vessel steno-occlusive progression with Onyx HD-500 and the utility of quantitative magnetic resonance imaging in serial assessment.
Topics: Angioplasty; Aspirin; Carotid Artery Diseases; Carotid Stenosis; Clopidogrel; Constriction, Patholog | 2013 |
Circulating microRNAs as novel biomarkers for platelet activation.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Blood Specimen Collection; Carotid Artery Diseases; Cas | 2013 |
A novel model of occlusive thrombus formation in mice.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Carotid Artery, Common; Dise | 2004 |
Progressive cervicocranial arteriopathy with dilatations and stenoses: case report.
Topics: Adult; Arterial Occlusive Diseases; Aspirin; Basilar Artery; Carotid Artery Diseases; Carotid Artery | 2004 |
[A case of common carotid artery dissection showing remission in short-term].
Topics: Antipyrine; Aortic Dissection; Aspirin; Carotid Artery Diseases; Carotid Artery, Common; Drug Therap | 2005 |
Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice.
Topics: Animals; Arteries; Aspirin; Bleeding Time; Blood Flow Velocity; Carotid Arteries; Carotid Artery Dis | 2005 |
Prophylactic aspirin therapy does not increase faecal calprotectin concentrations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Carotid Artery Diseases; Case-Control | 2006 |
Carotid stent failure: results of surgical rescue.
Topics: Aged; Angioplasty; Aspirin; Carotid Artery Diseases; Endarterectomy, Carotid; Female; Graft Occlusio | 2007 |
Aspirin reduces platelet aggregation during high-energy excimer laser.
Topics: Analysis of Variance; Angioplasty, Balloon, Laser-Assisted; Animals; Aspirin; Biomarkers; Carotid Ar | 2006 |
[Treatment of carotid artery aneurysms with covered stents].
Topics: Adult; Alloys; Angiography, Digital Subtraction; Angioplasty; Aortic Dissection; Aspirin; Carotid Ar | 2007 |
Antiplatelet agents for stroke prevention following transient ischemic attack.
Topics: Angioplasty, Balloon; Aspirin; Carotid Artery Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Com | 2008 |
Carotid occlusion and cerebral infarction from camel bite: case report.
Topics: Adult; Animals; Aphasia; Aspirin; Bites and Stings; Camelus; Carotid Arteries; Carotid Artery Diseas | 2007 |
Transient contralateral hemiplegia after ophthalmic zoster. Therapeutic problems in elderly patients.
Topics: Aged; Arteritis; Aspirin; Carotid Artery Diseases; Dipyridamole; Hemiplegia; Herpes Zoster Ophthalmi | 1981 |
Surgical management of the occluded carotid artery.
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebr | 1984 |
The significance of carotid stenosis or ulceration.
Topics: Angiography; Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Cerebral Infarction; Fem | 1984 |
The lame brain at the crossroads: which therapeutic road?
Topics: Aged; Aspirin; Carotid Artery Diseases; Cerebral Infarction; Cerebrovascular Disorders; Dipyridamole | 1984 |
Drugs in the treatment of thrombo-embolic disease--part I.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Carotid Artery Diseases; Cerebrovasc | 1983 |
The role of the neurologist in the decline of stroke.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Cerebral Infarction; Cerebrovascular Disorders; En | 1983 |
Etiologic factors for recurrent carotid artery stenosis.
Topics: Anesthesia; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Constriction, Pathologic; Coronary D | 1983 |
Non-steroidal anti-inflammatory agents and coronary heart disease.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Caroti | 1980 |
Transient cerebral ischaemic attacks.
Topics: Anticoagulants; Aspirin; Carotid Arteries; Carotid Artery Diseases; Diagnosis, Differential; Humans; | 1982 |
Scanning electron microscopic and X-ray energy spectrographic analysis of the inner surface of human atherosclerotic carotid plaques.
Topics: Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Dipyridamole; Female; Humans; Intracrani | 1981 |
Carotid vascular pain--a simple treatment.
Topics: Adolescent; Adult; Arteritis; Aspirin; Carotid Artery Diseases; Female; Humans; Male; Middle Aged; P | 1981 |
Aspirin failure in symptomatic atherosclerotic carotid artery disease.
Topics: Aged; Aspirin; Carotid Artery Diseases; Emergencies; Endarterectomy; Humans; Intracranial Arterioscl | 1981 |
The contralateral diseased but asymptomatic carotid artery: to operate or not? An update.
Topics: Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Endarterec | 1980 |
Anticoagulant treatment or antiplatelet therapy after a single carotid TIA?
Topics: Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Follow-Up Studies; Heparin; Humans; Isc | 1995 |
Risk factors for carotid atherosclerosis and platelet activation.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Fem | 1994 |
A follow-up survey of clinical practices for the use of heparin, warfarin, and aspirin.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Data Collection; Follow | 1994 |
In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis.
Topics: Animals; Aspirin; Carotid Artery Diseases; Carotid Artery Injuries; Carotid Artery, Common; Cerebrov | 1996 |
Stenting in the carotid artery: initial experience in 110 patients.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Carotid Artery | 1996 |
Spontaneous carotid dissection.
Topics: Adult; Aortic Dissection; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebrovascula | 1997 |
A late complication of internal carotid artery stenting.
Topics: Angioplasty; Anticoagulants; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Carotid Ste | 1998 |
Carotid occlusion mimicking giant cell arteritis.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blindness; Captopril; Carotid Artery Diseas | 1998 |
Detection of microemboli distal to cerebral aneurysms before and after therapeutic embolization.
Topics: Aneurysm; Anticoagulants; Aspirin; Basilar Artery; Brain Ischemia; Carotid Artery Diseases; Carotid | 1998 |
Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis.
Topics: Animals; Antifibrinolytic Agents; Antithrombins; Arterial Occlusive Diseases; Aspirin; Blood Platele | 1999 |
AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association.
Topics: Angioplasty; Anticoagulants; Aspirin; Carotid Artery Diseases; Humans; Ischemic Attack, Transient; P | 1999 |
Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity.
Topics: Aged; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Aspirin; Carotid Arteries; Carotid Artery | 2000 |
Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries.
Topics: Arteriosclerosis; Aspirin; Biopsy; Carotid Artery Diseases; Case-Control Studies; Cyclooxygenase 1; | 2000 |
Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests.
Topics: Aged; American Heart Association; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pressure; | 2001 |
Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels.
Topics: Analysis of Variance; Aspirin; Carotid Arteries; Carotid Artery Diseases; Carotid Stenosis; Endarter | 2002 |
Endothelial cell damage and thrombus formation following temporary arterial occlusion. Effects of pretreatment with aspirin or heparin.
Topics: Animals; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Circulation; Endotheliu | 1979 |
Management of the asymptomatic carotid bruit.
Topics: Aspirin; Auscultation; Carotid Artery Diseases; Cerebral Infarction; Cerebrovascular Disorders; Enda | 1979 |
Surgical grand rounds carotid artery surgery.
Topics: Anticoagulants; Arteriovenous Shunt, Surgical; Aspirin; Carotid Arteries; Carotid Artery Diseases; C | 1976 |
Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Atrial Fibrillation; Carotid Artery Diseases; Cerebral Infar | 1992 |
Report of dissection of the internal carotid artery in three cases.
Topics: Angiography, Digital Subtraction; Aortic Dissection; Aspirin; Carotid Artery Diseases; Carotid Arter | 1992 |
Prevention of stroke with ticlopidine: who benefits most? TASS Baseline and Angiographic Data Subgroup.
Topics: Aspirin; Carotid Artery Diseases; Cerebral Angiography; Cerebrovascular Disorders; Female; Humans; L | 1992 |
Horner's syndrome secondary to spontaneous carotid dissection with normal angiographic findings.
Topics: Angiography, Digital Subtraction; Aortic Dissection; Aspirin; Blood Pressure; Carotid Artery Disease | 1991 |
[Carotid endarterectomy for prevention of stroke: comparison of surgical and conservative therapy].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral | 1991 |
[Rapidly progressing carotid artery stenoses: possibilities of ultrasound prediction and effect of thrombocyte aggregation inhibitors].
Topics: Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Follow-Up Studies; Humans; Intracranial | 1990 |
Platelet scintigraphy and survival in juvenile stroke patients.
Topics: Adult; Arteriosclerosis; Aspirin; Blood Platelets; Carotid Arteries; Carotid Artery Diseases; Cell S | 1990 |
Aspirin reduces the growth of medial and neointimal thickenings in balloon-injured rat carotid arteries.
Topics: Animals; Aspirin; Carotid Arteries; Carotid Artery Diseases; Carotid Artery Injuries; Male; Rats; Ra | 1990 |
Patterns of failure of aspirin treatment in symptomatic atherosclerotic carotid artery disease.
Topics: Aged; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Cerebral Infarction; Humans; Middle Aged; | 1990 |
Transient ischaemic attacks.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Constriction, Pathologic | 1989 |
The role of carotid endarterectomy in asymptomatic carotid stenosis: status of the Veterans Administration study.
Topics: Arterial Occlusive Diseases; Aspirin; Carotid Arteries; Carotid Artery Diseases; Endarterectomy; Hum | 1989 |
Fibromuscular dysplasia of the carotid arteries complicating pregnancy.
Topics: Adult; Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Female; Fibromuscular Dysplasi | 1989 |
Late carotid restenosis: aetiologic factors for recurrent carotid artery stenosis during long-term follow-up.
Topics: Adult; Aged; Aspirin; Carotid Artery Diseases; Cholesterol; Cholesterol, HDL; Constriction, Patholog | 1989 |
Analysis of risk factors for myocardial infarction following carotid endarterectomy.
Topics: Arteriosclerosis; Aspirin; Carotid Artery Diseases; Coronary Disease; Endarterectomy; Female; Humans | 1989 |
Carotid and coronary artery involvement in infantile periarteritis nodosa possibly induced by Coxsackie B4 infection. Favourable course under corticosteroid treatment.
Topics: Aspirin; Carotid Artery Diseases; Coronary Disease; Coxsackievirus Infections; Dexamethasone; Dipyri | 1987 |
Indium-111-labeled platelet scintigraphy in carotid atherosclerosis.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Blood Platelets; Carotid Artery Diseases; | 1989 |
Bilateral loss of vision in bright light.
Topics: Aged; Aged, 80 and over; Aspirin; Blindness; Carotid Artery Diseases; Carotid Artery, External; Caro | 1989 |
Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo.
Topics: Angioplasty, Balloon; Animals; Aspirin; Carotid Arteries; Carotid Artery Diseases; Carotid Artery In | 1987 |
A seemingly simple decision.
Topics: Aged; Aspirin; Auscultation; Carotid Artery Diseases; Decision Theory; Dipyridamole; Endarterectomy; | 1987 |
Platelet kinetics following carotid endarterectomy: the effect of aspirin and patch angioplasty.
Topics: Aspirin; Blood Vessel Prosthesis; Carotid Arteries; Carotid Artery Diseases; Dipyridamole; Endartere | 1988 |
Carotid artery disease. A therapeutic enigma.
Topics: Aspirin; Blindness; Carotid Artery Diseases; Cerebrovascular Disorders; Endarterectomy; Eye Diseases | 1988 |
Aspirin, anticoagulants, and hemorrhagic conversion of ischemic infarction: hypothesis and implications.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Cerebral Hemorrhage; Cerebral Infarction; Heparin; | 1986 |
Management of transient ischemic attacks.
Topics: Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Embolism; | 1986 |
Prevention of postoperative neurologic deficits after carotid endarterectomy. Is platelet inhibition beneficial?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Dipyrid | 1987 |
Intraluminal thrombus of the internal carotid arteries: angiographic demonstration of resolution with anticoagulant therapy alone.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Female; Hepari | 1986 |
Spontaneous dissection of the carotid artery: an unusual cause of stroke in younger patients.
Topics: Adult; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral Angiography; Cerebrovasc | 1987 |
Transient ischemic attacks. Locating the source.
Topics: Aged; Aspirin; Blood Coagulation; Carotid Artery Diseases; Cerebrovascular Circulation; Diagnosis, D | 1985 |
Carotid endarterectomy. One solution to the stroke problem.
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebr | 1985 |
Peripheral vascular disease: treatment and referral of the elderly. Part II.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular | 1985 |
Stroke: malignant and benign syndromes.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Cerebral Hemorrhage; Cerebrovascular Disorders; De | 1973 |